ReviewMolecular diversity2026
Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fine-tuning LLM hyperparameters to align semantic and physiological contexts of aging-related pathways.Molecular diversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study explores the potential of phytochemicals as an innovative and successful strategy for mitigating symptoms of benign prostatic hyperplasia and prostate cancer. Prostate cancer is the most prevalent and second highest cause of mortality for men, with over 121 million cases worldwide. Finding no comprehensive study on the impact of compounds from all phytochemical classes in the perspectives of prostate disorders, this study analyzed data from a variety of investigations, including preclinical studies, in vitro and in vivo experiments, clinical trials, and cell line investigations, as part of a review of the literature. With a focus on mechanisms such as aging and hormonal factor modulation, apoptosis induction, overcoming inflammation, metabolic crisis, and medication resistance while minimizing side effects, the search concentrated on the effects of natural substances on prostate hyperplastic and malignant cells. The sequel of the study is suggestive of strong anti-hyperplastic and anti-cancerous potentials of phytochemicals in prostate cells. These phytochemicals have the capacity to target several pathways, providing a multifaceted approach to the therapy of BPH and prostate cancer. Interestingly, a large number of these substances exhibit negligible side effects, suggesting their possible use in clinical settings. The study unveils the mechanistic role of compounds belonging to various phytochemical classes in improving life quality and longevity in men with BPH and prostate cancer. Besides associating the existing literature, outcomes of the study ignite encouraging prospects towards further advancements in drug discovery and anticipation for prompt therapies.
Indexed as
Identifiers
40762933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.